{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.9","value":"9.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Cmax was defined as the observed maximum plasma concentration, obtained directly from the observed concentration at a steady state.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic population included all participants who received at least 1 dose of luspatercept and had measurable luspatercept serum concentrations.","reportingStatus":"POSTED","timeFrame":"Blood serum samples taken pre-dose at Cycle 1 Day 1 (C1, D1), C1 D8, C1 D15, C2 D1, C4 D1, C5 D8, C6 D1 and Week 25 visit, extension phase C4 D1 and Day 1 of every fourth treatment cycle thereafter.","title":"Pharmacokinetic (PK) Parameters: Bayesian Estimate of Maximum Concentration for the Starting Dose (Cmax) at Steady State","type":"SECONDARY","unitOfMeasure":"μg/mL"}